Compare Stocks: PEN, LNTH, ITGR, and EW

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EW Edwards Lifesciences	$85.23 +0.0%	$88.66	$72.30 ▼ $96.29	$49.03B	0.87	3.38 million shs	2.41 million shs
ITGR Integer	$126.47 +0.0%	$123.57	$62.00 ▼ $126.79	$4.30B	0.58	785,123 shs	471,806 shs
LNTH Lantheus	$99.96 +0.3%	$100.71	$49.67 ▼ $111.86	$6.52B	-0.06	976,694 shs	705,952 shs
PEN Penumbra	$317.74 -0.1%	$321.76	$221.26 ▼ $362.41	$12.51B	0.7	369,054 shs	239,678 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EW Edwards Lifesciences	+0.10%	-1.35%	-6.13%	-9.63%	+11.54%
ITGR Integer	+0.04%	+0.14%	+0.92%	+32.87%	+22.86%
LNTH Lantheus	+0.31%	+0.22%	-0.84%	-9.04%	+93.61%
PEN Penumbra	-0.12%	-0.42%	-1.62%	-0.25%	+27.36%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EW Edwards Lifesciences	$85.23 +0.0%	$88.66	$72.30 ▼ $96.29	$49.03B	0.87	3.38 million shs	2.41 million shs
ITGR Integer	$126.47 +0.0%	$123.57	$62.00 ▼ $126.79	$4.30B	0.58	785,123 shs	471,806 shs
LNTH Lantheus	$99.96 +0.3%	$100.71	$49.67 ▼ $111.86	$6.52B	-0.06	976,694 shs	705,952 shs
PEN Penumbra	$317.74 -0.1%	$321.76	$221.26 ▼ $362.41	$12.51B	0.7	369,054 shs	239,678 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EW Edwards Lifesciences	+0.10%	-1.35%	-6.13%	-9.63%	+11.54%
ITGR Integer	+0.04%	+0.14%	+0.92%	+32.87%	+22.86%
LNTH Lantheus	+0.31%	+0.22%	-0.84%	-9.04%	+93.61%
PEN Penumbra	-0.12%	-0.42%	-1.62%	-0.25%	+27.36%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EW Edwards Lifesciences	2.74	Moderate Buy	$100.27	17.65% Upside
ITGR Integer	2.07	Hold	$109.86	-13.13% Downside
LNTH Lantheus	2.29	Hold	$108.11	8.15% Upside
PEN Penumbra	2.18	Hold	$367.07	15.53% Upside

Current Analyst Ratings Breakdown

Latest PEN, LNTH, ITGR, and EW Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/25/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
9/14/2026	ITGR Integer	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
9/11/2026	EW Edwards Lifesciences	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$110.00
9/10/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
8/27/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/24/2026	PEN Penumbra	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/17/2026	LNTH Lantheus	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/13/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
8/13/2026	ITGR Integer	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/4/2026	LNTH Lantheus	CJS Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Market Outperform ➝ Market Perform
8/4/2026	ITGR Integer	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EW Edwards Lifesciences	$6.07B	8.09	$2.85 per share	29.86	$17.81 per share	4.79
ITGR Integer	$1.85B	2.32	$10.37 per share	12.20	$49.85 per share	2.54
LNTH Lantheus	$1.54B	4.23	$6.39 per share	15.65	$16.43 per share	6.08
PEN Penumbra	$1.40B	8.92	$4.30 per share	73.87	$36.45 per share	8.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EW Edwards Lifesciences	$1.07B	$1.74	48.98	25.14	2.23	15.43%	15.68%	12.05%	10/29/2026 (Estimated)
ITGR Integer	$102.81M	$3.66	34.55	18.85	2.40	6.97%	12.79%	6.48%	10/22/2026 (Estimated)
LNTH Lantheus	$233.56M	$4.14	24.14	18.31	N/A	17.69%	28.10%	14.35%	11/5/2026 (Estimated)
PEN Penumbra	$177.69M	$4.07	78.07	51.92	2.18	10.67%	10.50%	8.17%	11/4/2026 (Estimated)

Latest PEN, LNTH, ITGR, and EW Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/29/2026	Q3 2026	EW Edwards Lifesciences	$0.7380	N/A	N/A	N/A	$1.68 billion	N/A
10/22/2026	Q3 2026	ITGR Integer	$1.68	N/A	N/A	N/A	$456.91 million	N/A
8/6/2026	Q2 2026	LNTH Lantheus	$1.30	$1.55	+$0.25	$1.11	$363.23 million	$388.18 million
8/3/2026	Q2 2026	ITGR Integer	$1.38	$1.60	+$0.22	$0.69	$451.07 million	$464.11 million
7/30/2026	Q2 2026	PEN Penumbra	$1.16	$0.88	-$0.28	$0.88	$389.64 million	$390.05 million
7/23/2026	Q2 2026	EW Edwards Lifesciences	$0.7430	$0.78	+$0.0370	$0.42	$1.70 billion	$1.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EW Edwards Lifesciences	N/A	N/A	N/A	N/A	N/A
ITGR Integer	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
PEN Penumbra	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EW Edwards Lifesciences	0.06	4.52	3.77
ITGR Integer	0.75	3.73	2.41
LNTH Lantheus	0.43	3.06	2.89
PEN Penumbra	0.01	5.75	3.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EW Edwards Lifesciences	79.46%
ITGR Integer	99.29%
LNTH Lantheus	99.06%
PEN Penumbra	88.88%

Insider Ownership

Company	Insider Ownership
EW Edwards Lifesciences	0.31%
ITGR Integer	1.10%
LNTH Lantheus	1.70%
PEN Penumbra	2.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EW Edwards Lifesciences	16,000	575.80 million	574.02 million	Optionable
ITGR Integer	11,000	34.00 million	33.62 million	Optionable
LNTH Lantheus	1,193	65.27 million	64.16 million	Optionable
PEN Penumbra	4,700	39.39 million	38.25 million	Optionable

PEN, LNTH, ITGR, and EW Headlines

Recent News About These Companies

Boston Scientific keeps Penumbra deal on track as Penumbra stock costs EUR 284.00

October 3 at 5:20 PM | ad-hoc-news.deA

Penumbra stock breaks below 50-day average

October 1 at 2:54 PM | ad-hoc-news.deA

IART vs. PEN: Which Stock Is the Better Value Option?

October 1 at 12:41 PM | zacks.com

Penumbra (NYSE:PEN) Stock Price Breaks Below Fifty Day Moving Average - What's Next?

September 30 at 2:39 AM | marketbeat.com

IART or PEN: Which Is the Better Value Stock Right Now?

September 29, 2026 | zacks.com

Penumbra stock reports 14.9 percent revenue growth

September 24, 2026 | ad-hoc-news.deA

Penumbra Inc. stock trades near 317 dollars as investors weigh growth and valuation

September 20, 2026 | ad-hoc-news.deA

Bank of America Corp DE Purchases Shares of 266,017 Penumbra, Inc. $PEN

September 20, 2026 | marketbeat.com

Penumbra, Inc. $PEN Holdings Increased by HBK Investments L P

September 16, 2026 | marketbeat.com

Reasons to Retain Penumbra Stock in Your Portfolio for Now

September 16, 2026 | zacks.com

Penumbra, Inc. (NYSE:PEN) Given Consensus Recommendation of "Hold" by Analysts

September 14, 2026 | marketbeat.com

Engineers Gate Manager LP Purchases 14,086 Shares of Penumbra, Inc. $PEN

September 13, 2026 | marketbeat.com

TFX vs. PEN: Which Stock Is the Better Value Option?

September 11, 2026 | zacks.com

Amundi Has $34.70 Million Position in Penumbra, Inc. $PEN

September 11, 2026 | marketbeat.com

Penumbra Launches Link Clot Capture Device for Vascular Thrombectomy

September 10, 2026 | evtoday.comE

California State Teachers Retirement System Has $13.67 Million Stock Position in Penumbra, Inc. $PEN

September 10, 2026 | marketbeat.com

Squarepoint Ops LLC Sells 9,393 Shares of Penumbra, Inc. $PEN

September 9, 2026 | marketbeat.com

February 2027 lunar eclipse will be widely visible but barely noticeable

September 9, 2026 | msn.com

Penumbra, Inc. $PEN Shares Sold by Hsbc Holdings PLC

September 8, 2026 | marketbeat.com

Washington Trust Advisors Inc. Lowers Stock Holdings in Penumbra, Inc. $PEN

September 7, 2026 | marketbeat.com

Odyssean LLC Buys 4,932 Shares of Penumbra, Inc. $PEN

September 5, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PEN, LNTH, ITGR, and EW Company Descriptions

Edwards Lifesciences NYSE:EW

$85.23 +0.04 (+0.05%)

Closing price 10/2/2026 03:59 PM Eastern

Extended Trading

$85.55 +0.32 (+0.37%)

As of 10/2/2026 07:30 PM Eastern

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Integer NYSE:ITGR

$126.47 +0.05 (+0.04%)

Closing price 10/2/2026 03:59 PM Eastern

Extended Trading

$126.44 -0.03 (-0.02%)

As of 10/2/2026 07:30 PM Eastern

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac rhythm management, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.

Lantheus NASDAQ:LNTH

$99.96 +0.31 (+0.31%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$99.90 -0.06 (-0.07%)

As of 10/2/2026 07:30 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Penumbra NYSE:PEN

$317.74 -0.26 (-0.08%)

Closing price 10/2/2026 03:59 PM Eastern

Extended Trading

$317.63 -0.11 (-0.03%)

As of 10/2/2026 07:30 PM Eastern

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PEN, LNTH, ITGR, and EW Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PEN, LNTH, ITGR, and EW Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PEN, LNTH, ITGR, and EW Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PEN, LNTH, ITGR, and EW Company Descriptions

Edwards Lifesciences NYSE:EW

Integer NYSE:ITGR

Lantheus NASDAQ:LNTH

Penumbra NYSE:PEN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PEN, LNTH, ITGR, and EW Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PEN, LNTH, ITGR, and EW Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PEN, LNTH, ITGR, and EW Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PEN, LNTH, ITGR, and EW Company Descriptions

Edwards Lifesciences NYSE:EW

Integer NYSE:ITGR

Lantheus NASDAQ:LNTH

Penumbra NYSE:PEN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools